Integra LifeSciences Holdings Corporation

DB:IL3 Stock Report

Market Cap: €1.8b

Integra LifeSciences Holdings Valuation

Is IL3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IL3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IL3 (€23) is trading below our estimate of fair value (€59.04)

Significantly Below Fair Value: IL3 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IL3?

Key metric: As IL3 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IL3. This is calculated by dividing IL3's market cap by their current revenue.
What is IL3's PS Ratio?
PS Ratio1.2x
SalesUS$1.56b
Market CapUS$1.87b

Price to Sales Ratio vs Peers

How does IL3's PS Ratio compare to its peers?

The above table shows the PS ratio for IL3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.8x
DRW3 Drägerwerk KGaA
0.2x4.2%€792.0m
EUZ Eckert & Ziegler
3.2x6.3%€897.2m
AFX Carl Zeiss Meditec
2.5x8.0%€5.1b
SBS Stratec
1.3x7.7%€334.9m
IL3 Integra LifeSciences Holdings
1.2x5.8%€1.9b

Price-To-Sales vs Peers: IL3 is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does IL3's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$830.14m
PHH2 Paul Hartmann
0.3xn/aUS$781.42m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
IL3 1.2xIndustry Avg. 3.6xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IL3 is good value based on its Price-To-Sales Ratio (1.2x) compared to the European Medical Equipment industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is IL3's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IL3 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio2.1x

Price-To-Sales vs Fair Ratio: IL3 is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IL3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€23.00
€26.62
+15.7%
22.7%€37.88€19.89n/a9
Nov ’25€17.10
€24.46
+43.0%
29.2%€36.68€14.67n/a9
Oct ’25€16.20
€24.66
+52.2%
25.4%€36.14€14.45n/a10
Sep ’25€18.60
€24.92
+34.0%
22.9%€35.99€17.99n/a10
Aug ’25€22.80
€26.09
+14.4%
20.6%€37.00€20.35n/a10
Jul ’25€27.00
€31.60
+17.1%
32.3%€47.13€22.18n/a10
Jun ’25€28.40
€31.60
+11.3%
32.3%€47.13€22.18n/a10
May ’25€27.20
€41.45
+52.4%
14.3%€52.74€34.23n/a10
Apr ’25€32.00
€41.45
+29.5%
14.3%€52.74€34.23n/a10
Mar ’25€34.00
€41.45
+21.9%
14.3%€52.74€34.23n/a10
Feb ’25€37.00
€42.59
+15.1%
14.5%€52.10€33.82n/a10
Jan ’25€39.60
€41.90
+5.8%
15.3%€51.81€33.63n/a10
Dec ’24€35.80
€39.78
+11.1%
14.9%€50.56€33.09n/a11
Nov ’24€34.00
€40.35
+18.7%
15.0%€52.10€34.10€17.1010
Oct ’24€36.20
€42.82
+18.3%
12.9%€54.43€35.38€16.2010
Sep ’24€39.20
€42.82
+9.2%
12.9%€54.43€35.38€18.6010
Aug ’24€41.20
€42.82
+3.9%
12.9%€54.43€35.38€22.8010
Jul ’24€37.40
€43.98
+17.6%
16.2%€59.68€35.81€27.0010
Jun ’24€35.40
€45.67
+29.0%
16.1%€60.59€36.35€28.4010
May ’24€50.00
€52.44
+4.9%
8.3%€59.88€45.36€27.2010
Apr ’24€51.50
€55.66
+8.1%
11.5%€70.76€47.17€32.0010
Mar ’24€52.00
€55.66
+7.0%
11.5%€70.76€47.17€34.0010
Feb ’24€52.50
€54.28
+3.4%
12.4%€69.71€46.48€37.0010
Jan ’24€53.00
€53.59
+1.1%
13.8%€70.64€47.09€39.6010
Dec ’23€52.50
€51.78
-1.4%
15.3%€71.25€45.60€35.8010
Nov ’23€50.50
€54.68
+8.3%
15.3%€75.25€48.16€34.0010

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Sensus Healthcare

US$143.9m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$8.25

7D

4.4%

1Y

263.8%

Shandong Weigao Group Medical Polymer

HK$20.2b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.9%

1Y

-37.7%

LNA Santé

€240.3m

Engages in the management and operation of health establishments.

2N3

€23.00

7D

1.5%

1Y

17.7%